Mangiferin is a new potential antimalarial and anticancer drug for targeting serine hydroxymethyltransferase
5
item.page.dc.date.issued
2023-09-01
item.page.dc.type
item.page.dc.identifier.eissn
10960384
item.page.dc.identifier.doi
item.page.dc.identifier.scopus
2-s2.0-85168797531
item.page.dc.identifier.pmid
37543353
item.page.oaire.citation.title
Archives of biochemistry and biophysics
item.page.oaire.citation.volume
745
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
Archives of biochemistry and biophysics Vol.745 (2023) , 109712
punsarn.item.page.citation
Maenpuen S., Mee-udorn P., Pinthong C., Athipornchai A., Phiwkaow K., Watchasit S., Pimviriyakul P., Rungrotmongkol T., Tinikul R., Leartsakulpanich U., Chitnumsub P. Mangiferin is a new potential antimalarial and anticancer drug for targeting serine hydroxymethyltransferase. Archives of biochemistry and biophysics Vol.745 (2023) , 109712. doi:10.1016/j.abb.2023.109712 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/89279
item.page.dc.title
Mangiferin is a new potential antimalarial and anticancer drug for targeting serine hydroxymethyltransferase
item.page.dc.contributor.author
item.page.oairecerif.author.affiliation
item.page.dc.contributor.other
item.page.dc.description.abstract
Mangiferin, a polyphenolic xanthone glycoside found in various botanical sources, including mango (Mangifera indica L.) leaves, can exhibit a variety of bioactivities. Although mangiferin has been reported to inhibit many targets, none of the studies have investigated the inhibition of serine hydroxymethyltransferase (SHMT), an attractive target for antimalarial and anticancer drugs. SHMT, one of the key enzymes in the deoxythymidylate synthesis cycle, catalyzes the reversible conversion of l-serine and (6S)-tetrahydrofolate (THF) into glycine and 5,10-methylene THF. Here, in vitro and in silico studies were used to probe how mangiferin isolated from mango leaves inhibits Plasmodium falciparum and human cytosolic SHMTs. The inhibition kinetics at pH 7.5 revealed that mangiferin is a competitive inhibitor against THF for enzymes from both organisms. Molecular docking and molecular dynamic (MD) simulations demonstrated the inhibitory effects of the deprotonated forms of mangiferin, specifically the C6-O- species and its resonance C9-O- species appearing at pH 7.5, combined with two docked poses, either a xanthone or glucose moiety, placed inside the THF-binding pocket. The MD analysis revealed that both C6-O- and its resonance-stabilized C9-O- species can favorably bind to SHMT in a similar fashion to THF, supporting the THF competitive inhibition of mangiferin. In addition, characterization of the proton dissociation equilibria of isolated mangiferin revealed that only three hydroxy groups of the xanthone moiety, C6-OH, C3-OH, and C7-OH, underwent varying degrees of deprotonation with pKa values of 6.38 ± 0.11, 8.21 ± 0.35, and 12.37 ± 0.30, respectively, while C1-OH remained protonated. Altogether, our findings demonstrate a new bioactivity of mangiferin and provide the basis for the future development of mangiferin as a potent antimalarial and anticancer drug.